Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 16/20 | 0.55 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8473947 | 0.87 | ESR1 (0.58) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL4931312 | 0.86 | ESR1 (0.50) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL1358515 | 0.86 | ESR1 (0.63) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL5826407 | 0.86 | ESR1 (0.55) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL5420147 | 0.84 | ESR1 (0.58) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL4822091 | 0.83 | ESR1 (0.67) | ESR1ESR2 | |
| SCHEMBL8473855 | 0.83 | ESR1 (0.55) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL8474177 | 0.83 | ESR1 (0.57) | ESR1ESR2GCGRPSMB1PSMB5 | |
| SCHEMBL1359326 | 0.82 | ESR1 (0.63) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL1360090 | 0.82 | ESR1 (0.63) | ESR1ESR2PSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375229-B2 | Dihydro-dibenzo[B,E]oxepine based selective estrogen receptor modulators, compositions and methods | ELI LILLY AND COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375229-B2 | Dihydro-dibenzo[B,E]oxepine based selective estrogen receptor modulators, compositions and methods | ELI LILLY AND COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375229-B2 | Dihydro-dibenzo[B,E]oxepine based selective estrogen receptor modulators, compositions and methods | ELI LILLY AND COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20060142267-A1 | DIHYDRO-DIBENZO[B,E]OXEPINE BASED SELECTIVE ESTROGEN RECEPTOR MODULATORS, COMPOSITIONS AND METHODS | WALLACE OWEN B | 2006-06-29 | — | — | US | disclosed |
| US-7067510-B2 | Dihydro-dibenzo[b,e]oxepine based selective estrogren receptor modulators, compositions and methods | ELI LILLY AND COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1527076-B1 | DIHYDRO-DIBENZO[B,E]OXEPINE BASED SELECTIVE ESTROGEN RECEPTOR MODULATORS, COMPOSITIONS AND METHODS | LILLY CO ELI (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050240017-A1 | Dihydro-dibenzo[b,e]oxepine based selective estrogren receptor modulators, compositions and methods | ELI LILLY AND COMPANY | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142267-A1 | DIHYDRO-DIBENZO[B,E]OXEPINE BASED SELECTIVE ESTROGEN RECEPTOR MODULATORS, COMPOSITIONS AND METHODS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885GCGR 491/4885 |
| US-20050240017-A1 | Dihydro-dibenzo[b,e]oxepine based selective estrogren receptor modulators, compositions and methods | OXER1, GPER1, ESR1 | ESR1 3/4885ESR2 4/4885GCGR 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.